TG Therapeutics (NASDAQ:TGTX) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS

TG Therapeutics (NASDAQ:TGTX - Get Free Report) posted its quarterly earnings data on Monday. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.06, Zacks reports. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%.

TG Therapeutics Stock Up 14.4 %

TG Therapeutics stock traded up $4.33 during trading hours on Monday, hitting $34.42. The stock had a trading volume of 13,494,362 shares, compared to its average volume of 2,441,278. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The stock has a market capitalization of $5.36 billion, a P/E ratio of -344.17 and a beta of 2.26. TG Therapeutics has a 12-month low of $12.93 and a 12-month high of $36.84. The stock's 50-day moving average price is $30.79 and its 200-day moving average price is $28.24.

Analysts Set New Price Targets

A number of research analysts have recently commented on TGTX shares. The Goldman Sachs Group raised their target price on TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. raised their price objective on TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a research report on Monday, November 25th. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 target price on shares of TG Therapeutics in a research report on Wednesday, January 15th. Finally, StockNews.com cut shares of TG Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, January 31st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, TG Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $40.67.

Insider Transactions at TG Therapeutics

In related news, CFO Sean A. Power sold 10,021 shares of the business's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the transaction, the chief financial officer now directly owns 660,611 shares in the company, valued at $18,847,231.83. The trade was a 1.49 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 10.50% of the company's stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.